✅ Traditional CAR-T therapies require complex ex vivo manipulation of T cells, making them expensive, time-consuming, and inaccessible to many patients.

✅ Our in vivo CAR-T approach eliminates the need for ex vivo engineering, enabling direct immune reprogramming inside the body with enhanced precision and non-toxicity.

✅ This significantly improves accessibility while increasing the potent anti-tumor effects of CAR-T therapy.

✅ Refractory B-cell leukemia – Targeting CD19 to eliminate resistant leukemic cells.

✅ Non-Hodgkin lymphoma – Expanding in vivo CAR-T approaches to broader hematologic malignancies.

✅ Eliminates ex vivo manipulation, reducing manufacturing complexity and cost.
‍
✅ Potentially safer, reducing cytokine release syndrome and neurotoxicity.
‍
✅ Scalable & accessible, overcoming current CAR-T therapy limitations.

✅ Current treatments for autoimmune diseases rely on systemic immuno suppression, leading to significant side effects and increased infection risk.

✅ Our approach focuses on immune cell reprogramming, specifically targeting pathogenic B cells, T cells, and myeloid cells, to restore immune balance without compromising overall immune function.

✅ Type 1 Diabetes – Immune reprogramming to preserve or expand beta-cellfunction, preventing and/or curing disease progression.
✅ Arthritis Rheumatoid (AR) – Myeloid-targeted immune modulation to regulate inflammation and prevent joint damage

✅ Multiple Sclerosis (MS) – Myeloid-targeted therapies to modulate neuroinflammation and protect neuronal integrity

✅ Targets only disease-driving immune cells, preserving overall immune defense.
‍
✅ Avoids the risks of chronic immuno suppressive therapies.
‍
✅ Potential for long-term immune tolerance, reducing disease progression

✅ Chronic and drug-resistant infections remain one of the greatest global health threats.

✅ Our technology engineers the immune system to train and enhance guided clearance of viral and bacterial infections, offering a sustainable and morme effective alternative to traditional antivirals and antibiotics.

✅ HIV – Reprogramming immune cells to recognize and eliminate the virusdirectly, even before it infects the human cells, as well as eliminate latent reservoirs, moving towards a functional and definitive cure.
‍
✅ Multi-Drug Resistant Bacterial Infections – Engineering macrophages totarget and destroy antibiotic-resistant bacteria, reducing dependence on traditional antibiotics and offering a solution to resistant bacterias.

✅ Targets the immune system, not the pathogen, reducing the risk of drug resistance, and teach the immune system how to detect and eliminate the pathogen.
‍
✅ Long-lasting effects, unlike traditional antivirals or antibiotics, since improved clearance even before it infects the human cells.
‍
✅ Can be adapted to future emerging pathogens, offering pandemic preparedness solutions.

✅ Aging-related diseases result from cellular dysfunction, immune decline, andchronic inflammation.

✅ Our technology focuses on cellular reprogramming and immune system rejuvenation, enabling the regeneration of muscle, neural tissue, and metabolic function.

✅ Sarcopenia – Muscle regeneration through immune and metabolicreprogramming, counteracting age-related muscle loss.
‍
✅ Cognitive Decline / Neurodegeneration – Immune modulation to protect and restore neuronal function, starting with Alzheimer, but broadly applicable to Parkinson and other age-related cognitive impairments.

✅ Targets the root causes of aging, not just symptoms
‍
✅ Enhances immune function to prevent age-related disease progression.
‍
✅ Potential for regenerative therapy beyond current pharmacological approaches